Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Iris Energy Limited (IREN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Iris Energy Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Iris Energy Limited trades at $40.87 (market cap $14.23B). The key difference: Iris Energy Limited is far larger — about 3.2× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals.
| ACAD | IREN | |
|---|---|---|
Market Cap | $4.49B | $14.23B |
Sector | Health | Energy |
52-Week High | $28.06 | $76.41 |
52-Week Low | $20.06 | $15.40 |
Enterprise Value | $3.69B | $15.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
IREN stock trades at $43.91, up 13.11% today amid speculation about a potential $22 billion Anthropic deal. The technical picture remains bearish despite the rally, with the stock missing earnings expectations for three consecutive quarters. Revenue growth appears strong with 2026 projections showing $757 million, though profitability metrics show negative ROE and ROA. Analyst consensus remains bullish with a $79.11 price target despite recent volatility.
The investment case hinges on IREN's transition from Bitcoin mining to AI infrastructure, with significant capacity expansion funded by substantial financing activities. Key risks include execution challenges in scaling operations, competitive pressure from established cloud providers, and reliance on speculative contract wins. The current valuation at 57x P/E appears stretched given negative returns on equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →
